ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.718,85
0,35%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. LumiraDx Ltd (LMDX)

  7. LumiraDx Ltd (LMDX) News

LMDX

LumiraDx (LMDX)

LumiraDx Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LMDX
DatumZeitQuelleÜberschriftSymbolFirma
05/01/202423h45GlobeNewswire Inc.LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9thNASDAQ:LMDXLumiraDx Ltd
29/12/202323h07Dow Jones NewsLumiraDx Agrees to Sell Point-of-Care Tech Platform to RocheNASDAQ:LMDXLumiraDx Ltd
29/12/202322h15GlobeNewswire Inc.LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to RocheNASDAQ:LMDXLumiraDx Ltd
27/10/202322h45GlobeNewswire Inc.LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to AppealNASDAQ:LMDXLumiraDx Ltd
21/10/202300h34GlobeNewswire Inc.LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening HubNASDAQ:LMDXLumiraDx Ltd
24/08/202313h45GlobeNewswire Inc.LumiraDx Reports Second Quarter 2023 ResultsNASDAQ:LMDXLumiraDx Ltd
16/08/202322h30GlobeNewswire Inc.LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24NASDAQ:LMDXLumiraDx Ltd
31/07/202312h00GlobeNewswire Inc.LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and TestsNASDAQ:LMDXLumiraDx Ltd
30/06/202321h26Dow Jones NewsLumiraDx Submits Dual FDA Medical Device Application for Covid-19 TestNASDAQ:LMDXLumiraDx Ltd
30/06/202320h30GlobeNewswire Inc.LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra TestNASDAQ:LMDXLumiraDx Ltd
20/06/202322h15GlobeNewswire Inc.LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV TestsNASDAQ:LMDXLumiraDx Ltd
16/05/202313h45GlobeNewswire Inc.LumiraDx Reports First Quarter 2023 ResultsNASDAQ:LMDXLumiraDx Ltd
09/05/202322h15GlobeNewswire Inc.LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16NASDAQ:LMDXLumiraDx Ltd
24/04/202322h21GlobeNewswire Inc.LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:LMDXLumiraDx Ltd
06/04/202315h20GlobeNewswire Inc.LumiraDx Announces Strategic Refocus and Cost Restructuring ProgramNASDAQ:LMDXLumiraDx Ltd
21/03/202312h26GlobeNewswire Inc.LumiraDx Reports Fourth Quarter and Full Year 2022 ResultsNASDAQ:LMDXLumiraDx Ltd
14/03/202313h03GlobeNewswire Inc.LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21NASDAQ:LMDXLumiraDx Ltd
03/03/202315h00GlobeNewswire Inc.LumiraDx to Present at Raymond James Institutional Investors ConferenceNASDAQ:LMDXLumiraDx Ltd
20/02/202317h00GlobeNewswire Inc.LumiraDx Regains Compliance with Nasdaq Continued Listing RequirementsNASDAQ:LMDXLumiraDx Ltd
06/02/202314h59Dow Jones NewsLumiraDx Gets FDA Emergency Authorization for Dual Flu-COVID TestNASDAQ:LMDXLumiraDx Ltd
06/02/202314h00GlobeNewswire Inc.LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular AssayNASDAQ:LMDXLumiraDx Ltd
31/01/202322h30GlobeNewswire Inc.LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UKNASDAQ:LMDXLumiraDx Ltd
31/01/202322h15GlobeNewswire Inc.LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price DeficiencyNASDAQ:LMDXLumiraDx Ltd
14/12/202209h19GlobeNewswire Inc.LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis TestNASDAQ:LMDXLumiraDx Ltd
08/12/202209h01GlobeNewswire Inc.Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing CentersNASDAQ:LMDXLumiraDx Ltd
14/11/202215h44PR Newswire (US)LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c TestNASDAQ:LMDXLumiraDx Ltd
14/11/202215h41PR Newswire (US)LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c TestNASDAQ:LMDXLumiraDx Ltd
14/11/202215h41PR Newswire (Canada)LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c TestNASDAQ:LMDXLumiraDx Ltd
14/11/202208h58GlobeNewswire Inc.LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c TestNASDAQ:LMDXLumiraDx Ltd
14/11/202205h05TipRanksLumiraDx (LMDX) Gets a Buy from BTIGNASDAQ:LMDXLumiraDx Ltd
 Showing the most relevant articles for your search:NASDAQ:LMDX

Kürzlich von Ihnen besucht

DBI
TDXP
Tec DAX
NYSE
XOM
Exxon Mobil
NASDAQ
AMZN
Amazon.com
NASDAQ
MSFT
Microsoft
TG
DBK
Deutsche Bank
PM
XAUUSD
Gold vs US Dollar
NYSE
DIS
Walt Disney
NYSE
JPM
JP Morgan Chase
TG
RHM
Rheinmetall
USOTC
BNPQY
BNP Paribas (QX)
NYSE
KO
Coca Cola
NASDAQ
NVDA
NVIDIA
NYSE
MCD
McDonalds
FX
EURUSD
Euro vs US Dollar
FX
EURJPY
Euro vs Yen
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten